Treatment of dyslipoproteinemia in the metabolic syndrome

Summary:

The metabolic syndrome consists of a cluster of metabolic disorders, many of which promote the development of atherosclerosis and increase the risk to develop cardiovascular disease. The metabolic syndrome is characterized by atherogenic dyslipidemia (elevated triglycerides, increased small dense low-density lipoproteins, and decreased high-density lipoproteins), hypertension, insulin resistance and obesity. To decrease the risk of cardiovascular disease events decreasing body weight by ingesting a healthy diet, increasing physical activity, cessation of smoking and managing dyslipidemia are recommended. Pharmacological treatment of dyslipidemia is based on different drug classes. For LDL-cholesterol-lowering mainly statins and for triglyceride-lowering mainly fibrates are used. In primary and secondary prevention trials of heart disease they have shown to reduce the incidence of coronary artery disease or coronary events by 25-60 percent. Statins reduce mainly LDL-cholesterol levels by competitive inhibition of HMG-CoA reductase but have also shown to reduce fasting and postprandial triglyceride levels. Fibrates effectively reduce fasting and postprandial lipemia, shift the distribution of LDL particles towards less dense particles and increase HDL-cholesterol. Thus fibrates particularly address components of the metabolic syndrome and features of diabetic dyslipidemia. However studies still are needed showing definite evidence on differential therapy in lipid lowering based on prospective controlled trials with endpoints of macro- and microangiopathy in diabetic patients.

Abbreviations: BMI body mass index; CHD coronary heart disease; FFA free fatty acids; HDL high-density lipoprotein; HMG-CoA 3-hydroxy-3-methylglutaryl coenzyme A; IDL intermediate-density lipoprotein; LDL low-density lipoprotein; LPL lipoprotein lipase; NIDDM non-insulin-dependent diabetes mellitus; NO nitric oxide; PAI-1 plasminogen activator inhibitor-1; TRL triglyceride-rich lipoprotein; TG triglyceride; VLDL very-low-density lipoprotein

Key words:

Metabolic syndrome - dyslipidemia - diabetes - drug therapy - statins - fibrates

References

• 1 Abramowicz M. Choice of lipid lowering drugs (Editorial):.  Med Lett. 38 67-70 1996; 
• 2 American Diabetes Association . Management of dyslipidemia in adults with diabetes.  Diabetes Care. 21 536-539 1998; 
• 3 American Diabetes Association . Nutrition Recommendations and Principles for people with diabetes mellitus.  Diabetes Care 22 ((Suppl 1)) 1-9 1999; 
• 4 Arad Y, Ramakrishnan R, Ginsberg H N. Effects of lovastatin therapy on VLDL triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride rich lipoproteins.  Metabolism. 41 487-493 1992; 
• 5 Austin M A, Breslow J L, Hennekens C H, Curing J E, Willett W C, Krauss R M. LDL subclass patterns and risk of myocardial infarction.  JAMA. 260 1917-1921 1988; 
• 6 Austin M A, Hokansen J E, Edwards K L. Hypertriglyceridemia as a cardiovascular risk factor.  Am J Cardiol. 81 7B-12B 1998; 
• 7 Badrawy H S, Sayed S N, Gad A S, Shams E l, Din A A. Einfluß von Etofibrat auf die Blutglukose, Cholesterin and Triglyceride.  Therapiewoche. 34 1122-1129 1984; 
• 8 Bilheimer D W, Grundy S M, Brown M S, Goldstein J L. Mevinolin and colestipol stimulate receptor-mediated clearance of LDL from plasma in familial hypercholesterolemia heterozygotes.  Proc Natl Acad Sci USA. 80 4124-4128 1983; 
• 9 Blum C B. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.  Am J Cardiol. 73 3D-11D 1994; 
• 10 Blankenhorn D H, Hodis H N. Arterial imaging and atherosclerosis reversal.  Arterioscler Thromb. 14 177-192 1994; 
• 11 Brown B G, Hilger L, Zhao X Q, Poulin D, Albers J J. Types of change in coronary stenosis severitiy and their relative importance in overall progression and regression of coronary disease.  Ann NY Acad Sci. 748 407-417 1995; 
• 12 Brown W V. Lipoprotein disorders in diabetes mellitus.  Med Clin North Am. 78 143-161 1994; 
• 13 Cambien F, Jacqueson A, Richard J L, Warnet J M, Ducimetiere P, Claude J R. Is the level of serum triglyceride a significant predictor of coronary death in “normocholesterolemic” subjects? The Paris Prospective Study.  Am J Epidemiol. 124 624-632 1986; 
• 14 Canner P L, Berge K G, Wenger N K, Stamler J, Friedman L, Prineas R J, Friewald W. Fifteen year mortality in Coronary Drug Project Patients: long-term benefit with niacin.  J Am Coll Cardiol. 8 1245-1255 1986; 
• 15 Carlson L A, Aberg H. Serum triglycerides - an independent risk factor for myocardial infartion but not for angina pectoris.  N Engl J Med. 312 1127 1985; 
• 16 Castelli W P. The triglyceride issue: a view from Framingham.  Am Heart J. 112 432-437 1986; 
• 17 Christiansen C, Thomsen C, Rasmussen O, Hansen C, Hermansen K. The acute impact of ethanol on glucose, insulin, triacylglycerol,and free fatty acid responses and insulin sensitivity in type 2 diabetes.  Br J Nutr. 76 669-675 1996; 
• 18 Colli S, Eligini S, Lalli M, Camera M, Paoletti R, Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages: a novel mechanism of protection against atherothrombosis.  Arterioscler Thromb Vasc Biol. 17 265-272 1997; 
• 19 Coronary Drug Project Research Group . Clofibrate and niacin in coronary heart disease.  JAMA. 231 360-381 1975; 
• 20 Davignon J, Montigny M, Dufour R. HMG-CoA reductase inhibitors: a look back and a look ahead.  Can J Cardiol. 8 843-864 1992; 
• 21 Downs J R, Clearfield M, Weis S, Whitney E, Shapiro D R, Beere P A, Langendorfer A, Stein E A, Kryer W, Gotto A M. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.  JAMA. 270 1615-1622 1998; 
• 22 Ebenbichler C F, Kirchmair R, Egger C, Patsch J R. Postprandial state and atherosclerosis.  Curr Opin Lipidol. 6 286-290 1995; 
• 23 Fonseca F A, Novazzi J P, Cendoroglo M S, Duarte M, Almeida Pinto L E, Rabelo L M, da Rocha Martinez T L. Lipid changes of fibrinogen and of platelet aggregation induced by etofibrate.  Arq Bras Cardiol. 66 33-35 1999; 
• 24 Fontbonne A, Eschwege E, Cambien F, Richadr J L, Ducimetiere P, Thibult N, Warnet J M, Claude J R, Rosselin G E. Hypertriglyceridemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study.  Diabetologia. 32 300-304 1989; 
• 25 Franz M J, Horton E S, Bantle J P, Beebe C A, Brunzell J D, Coulston A M, Henry R R, Hoogwerf B J, Stacpoole P W. Nutrition principles for the management of diabetes and related complications.  Diabetes Care. 17 490-518 1994; 
• 26 Frick M H, Elo O, Haapa K, Heinonen O P, Heinsalmi P, Helo P, Huttunen J K, Kaitaniemi P, Koskinen P, Manninen V. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.  N Engl J Med. 317 1237-1245 1987; 
• 27 Fruchart J C, Brewer H B, Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group.  Am J Cardiol. 81 912-917 1998; 
• 28 Gardner C D, Fortmann S P, Krauss R M. Association of small LDL particles with the incidence of coronary artery disease in men and women.  JAMA. 276 875-881 1996; 
• 29 Goldberg R B, Mellies M J, Sacks F M, Moye L A, Howard W J, Davis B R, Cole T G, Pfeffer M A, Braunwald E. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocrdial infarction survivors with average cholesterol and recurrent events (CARE) trail. The Care Investigators.  Circulation. 98 2513-2519 1998; 
• 30 Grieve D J, Avella M A, Elliott J, Botham K M. The influence of chylomicron remnants on endothelial cell function in the isolated perfused rat aorta.  Atherosclerosis. 139 273-281 1998; 
• 31 Groot P HE, van Stiphout W AHJ, Krauss X H, Jansen H, van Tol A, van Ramshorst E, Chin-On S, Hofman A, Cresswell S R, Havekes L. Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease.  Atheroscler Thromb. 11 653-662 1991; 
• 32 Haffner S M, Alexander C M, Cook T J, Boccuzzi S J, Musliner T A, Pedersen T R, Kjekshus J, Pyörälä K. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Sandinavian Simvastatin Survival Study.  Arch Intern Med. 159 2661-2667 1999; 
• 33 Haire-Joshu D, Glasgow R E, Tibbs T L. Smoking and diabetes.  Diabetes Care. 22 1887-1889 1999; 
• 34 Hanston P D, Horn J R. Drug interactions with HMG CoA reductase inhibitors. Drug Interaction Newsletters.  (Vancouver, Wa.: Applied Therapeutics.). 103-106 1998; 
• 35 Hardman A E. Physical activity, obesity and blood lipids.  Int J Obes Relat Metab Disord 23 ((Suppl 3)) S64-S71 1999; 
• 36 Havel R J. Postprandial hyperlipidemia and remnant lipoproteins.  Curr Opin Lipidol. 5 102-109 1994; 
• 37 Heinonen O P, Huttunen J K, Manninen V, Manttari M, Koskinen P, Tenkanen L, Frick M H. The Helsinki Heart Study: coronary heart disease incidence during an extended follow-up.  J Intern Med. 235 41-49 1994; 
• 38 Herrera E, Lasuncion M A, Castro M, Gomez-Coronado D, Martin A, Quack G. Studies with etofibrate in the rat. Part I:effects on glycerol, free fatty acid and triacylglycerol metabolism.  Biochim Biophys Acta. 963 42-52 1988; 
• 39 Heyden S, Hames C G. Triglycerides and coronary heart disease.  N Engl J Med. 303 1061 1980; 
• 40 Hodis H N, Mack W J. Triglyceride-rich lipoproteins and the progression of coronary artery disease.  Curr Opin Lipidol. 6 209-214 1995; 
• 41 Hodis H N, Mack W J, Dunn M, Liu C, Selzer R H, Krauss R M. Intermediate-density lipoproteins and progression of caroid wall intima-media thickness.  Circulation. 95 2022-2026 1997; 
• 42 Hodis H N, Mack W J. Triglyceride-rich lipoproteins and progression of atherosclerosis.  Eur Heart J. 19 A40-A44 1998; 
• 43 Hollander P A, Elbein S C, Hirsch I B, Kelley D, McGill J, Taylor T, Weiss S R, Crockett S E, Kaplan R A, Comstock J, Lucas C P, Lodewick P A, Canovatchel W, Chung J, Hauptman J. Role of orlistat in the treatment of obese patients with type 2 diabetes.  Diabetes Care. 21 1288-1294 1998; 
• 44 Howard B V, Robbins D C, Sievers M L, Lee E T, Rhoades D, Devereux R B, Cowan L D, Gray R S, Welty T H, Go O T, Howard W J. LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL.  Arteroscler Thromb Vasc Biol. 20 830-835 2000; 
• 45 Jagla A, Schrezenmeir J. Induction of E-selectin expression by oxidized chlylomicrons.  Diabetologia 41 ((Suppl 1)) A137 1998; 
• 46 Jastrzebska M, Torbus-Lisiecka B, Pieczul-Mroz J, Chelstowski K, Kopciewicz J, Naruszewicz M. Etofibrate decreases factor VII and fibrinogen levels in patients with polymetabolic syndrome.  Int J Clin Pharmacol Res. 19 19-25 1999; 
• 47 Jukema J W, Bruschke A V, van Boven A J, Reiber J H, Bal E T, Zwinderman A H, Jansen H, Boerma G J, van Rappard F M, Lie K I. on behalf of the REGRESS Study Group Interuniversity Cardiology Institute Utrecht Netherlands: Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).  Circulation. 91 2528-2540 1995; 
• 48 Kaesemeyer W H, Caldwell R B, Huang J, Caldwell R W. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions.  J Am Coll Cardiol. 33 234-241 1999; 
• 49 Karpe F, Steiner G, Olivecrona T, Carlson L A, Hamsten A. Metabolism of triglyceride-rich lipoproteins during alimentary lipemia.  J Clin Invest. 91 748-758 1993; 
• 50 Knopp R H. Drug treatment of lipid disorders.  N Engl J Med. 341 498-511 1999; 
• 51 Koskinen P, Manttari M, Manninen V, Huttunen J K, Heinonen O P, Frick M H. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study:.  Diabetes Care. 15 820-825 1992; 
• 52 Kraemer F B, Chen Y D, Lopez R D, Reaven G M. Effects of noninsulin-dependent diabetes mellitus on the uptake of very low density lipoproteins by thioglycate-elicited mouse peritoneal macrophages.  J Clin Endocrinol. 61 335-342 1985; 
• 53 Kurtel H, Liao L, Grisham M B, Tso P, Aw T Y, Anderson D C, Miyasaka M, Granger D N. Mechanisms of oxidized chylomicron-induced leukocyte-endothelial cell adhesion.  Am J Physiol. 268 H2175-H2182 1995; 
• 54 Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais G R, Lupien P J, Depres J P. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study.  Circulation. 95 69-75 1997; 
• 55 Lean M E, Powrie J K, Anderson A S, Gathwaite P H. Obesity, weight loss and prognosis in type 2 diabetes.  Diabet Med. 7 228-233 1990; 
• 56 Leiss O, von Bergmann K, Gnasso A, Augustin J. Effect of gemfibrozil on biliary lipid metabolism in normolipemic subjects.  Metabolism. 34 74-82 1985; 
• 57 Leitersdorf E, Muratti E N, Eliav O, Meiner V, Eisenberg S, Dann E J, Sehayek E, Peters T K, Stein Y. Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination.  Am J Med. 96 401-407 1994; 
• 58 Levenson J L, Giral P, Razavian M, Gariepy J, Simon A. Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors.  Arterioscler Thromb Vasc Biol. 15 1263-1268 1995; 
• 59 MAAS investigators . Effect of simvastatin on coronary atheroma: the multicentre anti-atheroma study (MAAS).  Lancet. 344 633-638 1994; 
• 60 Mabile L, Meilhac O, Escargueil-Blanc I, Troly M, Pieraggi M T, Salvayre A. Mitrochondrial function is involved in LDL oxidation mediated by human cultured endothelial cells.  Arterioscler Thromb Vasc Biol. 17 1575-1582 1997; 
• 61 Mikhailidis D P, Papadakis J A, Ganotakis E S. Smoking, diabetes and hyperlipidemia.  J R Soc Health. 118 91-93 1998; 
• 62 Miesenböck G, Patsch J R. Postprandial hyperlipidemia: the search for the atherogenic lipoprotein.  Curr Opin Lipidol. 3 196-201 1992; 
• 63 Moers-Jagla A, Fenselau S, Schrezenmeir J. Chylomicrons induce E-selectin and VCAM-1 expression in endothelial cells.  Exp Clin Endocrinol Diab 105 ((Suppl 1)) 35-37 1997; 
• 64 Mosca L, Grundy S M, Judelson D, King K, Limacher M, Oparil S, Pasternak R, Pearson T, Redberg R F, Smith S C, Winston M, Zinberg S. Guide to preventive cardiology for women.  Circulation. 99 2480-2484 1999; 
• 65 Mühlhauser I. Cigarette smoking and diabetes: an update.  Diabet Med. 11 336-343 1994; 
• 66 Niort G, Gambino R, Cassander M, Pagano G. Bezafibrate affects lipid, lipo- and apolipoprotein pattern in NIDDM patients.  Horm Metab Res. 25 372-374 1993; 
• 67 O'Driscoll G, Green D, Taylor R R. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month.  Circulation. 95 1126-1131 1997; 
• 68 Okuda Y, Kawashima K, Sawada T, Tsurumaru K, Asano M, Suzuki S, Soma M, Nakajima T, Yamashita K. Eicosapentanoic acid enhances nitric oxide production by cutured human endothelial cells.  Biochem Biophys Res Commun. 232 487-491 1997; 
• 69 Opper C, Clement C, Schwarz H, Krappe J, Steinmetz A, Schneider J, Wesemann W. Increased number of high sensitive platelets in hypercholesterolemia, cardiovascular diseases, and after incubation with cholesterol.  Atherosclerosis. 113 211-217 1995; 
• 70 Pelkonen R, Nikkila E A, Koskinen S, Penttinen K, Sarna S. Association of serum lipids and obesity with cardiovascular mortality.  Br Med J. 2 1185-1187 1977; 
• 71 Plotnick G D, Corretti M C, Vogel R A. Effect of antioxidant vitamins on the transient impairment of endothelium-dependent brachial artery vasoactivity following a single high-fat meal.  JAMA. 278 1682-1686 1997; 
• 72 Pyörälä K, Pedersen T R, Kjekshus J, Faergeman O, Olsson A G, Thogeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S).  Diabetes Care. 20 614-620 1997; 
• 73 Raedsch R, Plachky J, Wolf N, Simonis G. Biliary lipids, lithogenic index and biliary drug concentrations during etofibrate and bezafibrate treatment.  Eur J Drug Metab Pharmacokinet. 20 113-118 1995; 
• 74 Rapp J H, Lespine A, Hamilton R L, Colyvas N, Chaumeton A H, Tweedie-Hardman J, Kotite L, Kunitake S T, Havel R J, Kane J P. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque.  Arterioscler Thromb. 14 1767-1774 1994; 
• 75 Reitsma J B, Castro-Cabezas M, de Bruin T WA, Erkelens D W. Relationship between improved postprandial lipemia and LDL metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor.  Metabolism. 43 293-298 1994; 
• 76 Rosenson R S, Tangney C C. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction.  JAMA. 279 1643-1650 1998; 
• 77 Ross R. Atherosclerosis-an inflammatory disease.  N Engl J Med. 340 115-126 1999; 
• 78 Rubins H B, Robins S J, Collins D, Fye C L, Anderson J W, Elam M B, Faas F H, Linares E, Schaefer E J, Schectman G, Wilt T J, Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol.  N Engl J Med. 341 410-418 1999; 
• 79 Saxena U, Kulkarni N M, Ferguson E, Newton R S. Lipoprotein lipase mediated lipolysis of VLDL increases monocyte adhesion to aortic endothelial cells.  Biochem Biophys Res Commun. 189 1653-1658 1992; 
• 80 Schrezenmeir J, Keppler I, Fenselau S, Weber P, Biesalski H K, Probst R, Laue Ch, Zuchhold H D, Prellwitz W, Beyer J. The phenomenon of a high triglyceride response to an oral lipid load in healthy subjects and its link to the metabolic syndrome.  Ann NY Acad Sci. 683 302-314 1993; 
• 81 Schrezenmeir J. Hyperinsulinemia, hyperproinsulinemia and insulin resistance in the metabolic syndrome.  Experientia. 52 426-432 1996; 
• 82 Schrezenmeir J, Fenselau S, Keppler I, Clark B, Abel J, Orth B, Laue Ch, Stürmer W, Fauth U, Halmagyi M, Hales C N. Postprandial triglyceride high response and the metabolic syndrome.  Ann NY Acad Sci. 827 353-368 1997; 
• 83 Silveira A. Postprandial triglycerides and coagulation.  Exp Clin Endocrinol Diab. 109 S527-S532 2001; 
• 84 Simons L A, Dwyer T, Simons J, Bernstein L, Mock P, Poomnia N S, Balasubramaniam S, Baron D, Branson J, Morgan J, Roy P. Chylomicrons and chylomicron remnants in coronary artery disease: a case control study.  Atherosclerosis. 65 181-189 1987; 
• 85 Simpson H S, Williamson C M, Olivecrona T, Pringle S, Maclean J, Lorimer A R, Bonnefous F, Bogaievsky Y, Packard C J, Shepherd J. Postprandial lipemia, fenofibrate and CAD.  Atherosclerosis. 85 193-202 1990; 
• 86 Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart J C. Mechanism of action of fibrates on lipid and lipoprotein metabolism.  Circulation. 98 2088-2093 1998; 
• 87 Steinmetz A, Schwartz T, Hehnke U, Kaffarnik H. Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia.  J Cardiovasc Pharmacol. 27 563-570 1996; 
• 88 Stern M P, Haffner S M. Dyslipidemia in type II diabetes. Implications for therapeutic intervention.  Diabetes Care. 14 1144-1159 1991; 
• 89 Syvänne M, Taskinen M R. Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus.  Lancet. 350 20-23 1997; 
• 90 Taskinen M R. Strategies for the management of diabetic dyslipidemia.  Drugs ((Suppl I)) 47-51 1999; 
• 91 Taskinen M R. Triglyceride is the major atherogenic lipid in NIDDM.  Diabetes Metab Rev. 13 93-98 1997; 
• 92 The West of Scotland Coronary Prevention Study Group . Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOCOPS).  Circulation. 97 1440-1445 1998; 
• 93 Treasure C B, Klein J L, Wintraub W S, Talley J D, Stillabower M E, Kosinski A S, Zhang J, Bocuzzi S J, Cedarhoolm J C, Alexander R W. Beneficial effects of cholestrol-lowering therapy on the coronary endothelium in patients with coronary artery disease.  N Engl J Med. 332 481-487 1995; 
• 94 Vinik A I, Colwell J A. Effects of gemfibrozil on triglyceride levels in patients with NIDDM. Hyperlipidemia in Diabetes Investigators.  Diabetes Care. 16 37-44 1993; 
• 95 Virgolini I, Koller E, Li S, Yang O, Banyai M, Rauscha F, Pidlich J, Pirker W, Sinziger H. Etofibrate increases binding of low and high density lipoprotein to human platelets of patients with type II hyperlipoproteinemia.  Atherosclerosis. 102 217-226 1993; 
• 96 Vogel R A, Corretti M C, Plotnick G D. Effect of a single high-fat meal on endothelial function in healthy subjects.  Am J Cardiol. 79 350-354 1997; 
• 97 Weber P, Schrezenmeir J, Fenselau S, Ausieker S, Probst R, Zuchhold H D, Prellwitz W, Beyer J. Prolonged postprandial increment in triglycerides and decreased postprandial response of VLDL in type 2 diabetics following an oral lipid load.  Ann NY Acad Sci. 683 315-322 1993; 
• 98 Weintraub M S, Grosskopf I, Rassin T, Miller H, Charach G, Rotmensch H H, Liron M, Rubinstein A, Laina A. Clearance of chylomicron remnants in normolipidemic patients with coronary artery disease: case control study over three years.  Br Med J. 312 935-939 1996; 
• 99 Yudkin J S. Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent?.  Diabetes Care 22 ((Suppl 3)) C25-C30 1999;